Kallyope Is A Biotechnology Company Based In New York Cityfounded In 2015 By Notable Scientists Including Nobel Laureate Richard Axelthe Company Specializes In Understanding The Gut Brain Axiswhich Is The Communication Pathway Between The Gastrointestinal System And The Nervous Systemkallyope Aims To Develop Therapeutics For Neurological And Metabolic Diseasesemploying A Multidisciplinary Approach That Includes Advanced Technologies Like Single Cell Sequencing And Computational Biology The Company Has A Robust Pipeline Of Drug Candidates Targeting Conditions Such As Obesitydiabetesand Gastrointestinal Disorderskallyope Focuses On Creating Effective And Patient Friendly Oral Or Systemic Agents That Modulate Gut Brain Signaling Pathwayswith A Team Of 91 Employees And Significant Fundingincluding A $236 Million Series D Round In 2022Kallyope Is Committed To Advancing Its Therapeutic Programs And Expanding Its Research Capabilities
